Drug recall · September 12, 2018
AvKARE Valsartan and Hydrochlorothiazide 320 mg/12.5 mg tablets recall
Why: CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
AvKARE Valsartan and Hydrochlorothiazide 320 mg/12.5 mg tablets, 90-count bottle, Rx Only, Manufactured for: AvKARE, Inc. Pulaski, TN 38478, NDC 42291-886-90
- Lots / codes
Lots: 17780 Exp. 09/2018; 18029 Exp. 09/2018; 18398 Exp. 09/2018; 18723 Exp. 09/2018; 19017 Exp. 02/2019; 19224 Exp. 02/2019; 20032 Exp. 08/2019; 20289 Exp. 08/2019; 21076 Exp. 08/2019; 21382 Exp. 08/2019
- Quantity
- 12950 bottles
- Company
- Avkare Incorporated, Pulaski, TN
- Distribution
- Nationwide
- Initiated
- July 18, 2018 · Voluntary: Firm initiated
- Classified
- September 6, 2018
- Reported
- September 12, 2018
- Ended
- May 7, 2020
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Hydrochlorothiazide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.